ArticleJournal of Brown hospital medicine2025
Dual Antibody Positive Rheumatoid Feet.
Article in Journal of Brown hospital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An 86-year-old man presented with severe, debilitating, dual antibody positive rheumatoid arthritis associated joint deformities of his upper and lower extremities. These developed over twenty years but were progressive and debilitating. They began in the forefoot and eventually progressed to mid and hindfoot bilaterally. Examination of his lower extremities revealed severe bilateral hallux valgus deformities, traumatic pes planus deformity, right foot metatarsal head subluxation, and bilateral claw and hammer toes. Relentless progression of his lower extremity pain, joint destruction and significant gait limitation was due to a constellation of factors including ongoing tobacco use, dual antibody positivity and intolerance based on side effects to multiple targeted biologic disease-modifying antirheumatic (DMARD) medications including infliximab, etanercept, golimumab and tofacitinib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.